By: Julia Cipriano, MS, CMPP Posted: Tuesday, February 17, 2026 In a comparison of current efficacy and safety data for KRAS G12C inhibitors, sotorasib demonstrated greater cost-effectiveness than adagrasib for second- and subsequent-line treatment of KRAS G12C–mutated non–small cell lung...
KRAS is one of the most frequently mutated oncogenes in lung adenocarcinoma (LUAD), with the KRAS-Q61H mutation representing a rare but biologically distinct Introduction Lung adenocarcinoma is the most common histologic subtype of non-small cell lung cancer (NSCLC) and is...
You are reading this latest preprint version Background Pulmonary sarcomatoid carcinoma (PSC) is a rare, highly aggressive non-small cell lung cancer (NSCLC) subtype (0.1%–4% of lung malignancies)[3]. Clinically, it mainly affects smokers, with half diagnosed at advanced stages; pathologically, it...
KRAS is one of the most frequently mutated oncogenes in non-small cell lung cancer (NSCLC), particularly in lung adenocarcinoma, with mutation rates ranging Highlights • First comprehensive synthesis of monotherapy and combination strategies for KRAS G12C-mutant NSCLC, integrating latest clinical...
Abstract KRAS G12S mutations in non-small cell lung cancer (NSCLC) remain refractory to current targeted therapies, with few clinical options and frequent resistance. While CRISPR/Cas9 enables mutation-specific gene disruption, its pulmonary application is limited by systemic clearance, hepatic tropism, and...
